|
Jun 20
|
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
|
|
Jun 20
|
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
|
|
Jun 19
|
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
|
|
Jun 17
|
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
|
|
Jun 17
|
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
|
|
Jun 16
|
Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy
|
|
Jun 16
|
Genentech Provides Update on Phase III Verona Study
|
|
Jun 16
|
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
|
|
Jun 16
|
Sarepta and Roche halt DMD gene therapy’s use after second death
|
|
Jun 16
|
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
|
|
Jun 16
|
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
|
|
Jun 15
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
|
|
Apr 25
|
Roche’s diagnostic sales hit by China pricing reforms
|
|
Apr 25
|
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
|
|
Apr 24
|
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
|
|
Apr 24
|
Drugmakers brace for Trump tariffs, while weighing numerous other worries
|
|
Apr 24
|
Repertoire and Genentech to develop autoimmune disease therapies
|
|
Apr 24
|
Roche introduces algorithm for ACS detection in individuals with chest pain
|
|
Apr 24
|
Roche seeks US tariff relief in direct talks with Trump administration
|
|
Apr 24
|
Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push
|